{"id":9496,"date":"2026-09-16T15:40:00","date_gmt":"2026-09-16T13:40:00","guid":{"rendered":"https:\/\/mumak.me\/?p=9496"},"modified":"2026-09-16T16:06:14","modified_gmt":"2026-09-16T14:06:14","slug":"red-hot-chili-mumak-of-the-week-no-award-this-week","status":"publish","type":"post","link":"https:\/\/mumak.me\/en\/portfolio-updates\/red-hot-chili-mumak\/red-hot-chili-mumak-of-the-week-no-award-this-week\/","title":{"rendered":"RED HOT CHILI\u2122 MUMAK of the Week: No Award This Week"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"9496\" class=\"elementor elementor-9496 elementor-9495\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-21f229a e-flex e-con-boxed e-con e-parent\" data-id=\"21f229a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7f0c607 elementor-widget elementor-widget-text-editor\" data-id=\"7f0c607\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"120\" data-end=\"274\">The current portfolio environment offers no company that shows a sufficiently strong alignment across all five analysis levels of the RED HOT CHILI\u2122 MUMAK.<\/p><h3 data-start=\"276\" data-end=\"342\"><strong data-start=\"276\" data-end=\"342\">Why the RED HOT CHILI\u2122 MUMAK is not being awarded this week<\/strong><\/h3><p data-start=\"344\" data-end=\"495\">With the RED HOT CHILI\u2122 MUMAK, we recognize the company that currently shows the strongest alignment across our five analysis levels:<\/p><ul data-start=\"497\" data-end=\"598\"><li><strong>Geopolitics<\/strong><\/li><li><strong>Industry<\/strong><\/li><li><strong>Fundamentals<\/strong><\/li><li><strong>News &amp; Market Sentiment<\/strong><\/li><li><strong>Technical Analysis<\/strong><\/li><\/ul><p data-start=\"600\" data-end=\"708\">This week, none of the companies in the UMBRELLA Strategy convincingly meet these requirements.<\/p><p data-start=\"710\" data-end=\"930\">The UMBRELLA Strategy continues to include several companies with constructive long-term prospects. However, short-term momentum is mixed, and technical signals are not consistently supportive.<\/p><h3 data-start=\"932\" data-end=\"993\"><strong data-start=\"932\" data-end=\"993\">Revolution Medicines comes closest to an award<\/strong><\/h3><p data-start=\"995\" data-end=\"1202\"><strong><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-revolution-medicines\/\">Revolution Medicines<\/a><\/strong> is currently the position with the strongest performance in the portfolio. Since its inclusion, it has recorded a price gain of around 26.1% and has a weighting of approximately 18.2%.<\/p><p data-start=\"1204\" data-end=\"1435\">The company also received another Breakthrough Therapy designation from the FDA for RASONQUE (Daraxonrasib), this time in combination with chemotherapy for the first-line treatment of metastatic pancreatic cancer.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-117ef65 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"117ef65\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"elementor-heading-title elementor-size-default\"><strong><a href=\"https:\/\/mumak.me\/en\/portfolio-updates\/company-update\/revolution-medicines-update-fda-breakthrough-therapy-designation-expands-rasonques-potential\/\">Revolution Medicines Update: FDA Breakthrough Therapy designation expands RASONQUE\u2019s potential<\/a><\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4ed238c elementor-widget elementor-widget-text-editor\" data-id=\"4ed238c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"1443\" data-end=\"1629\">However, the positive development has already been accompanied by a significant price increase. Revolution Medicines therefore remains a company that should continue to be closely monitored.<\/p><h3 data-start=\"1631\" data-end=\"1697\"><strong data-start=\"1631\" data-end=\"1697\">Micron cannot confirm last week&#8217;s momentum<\/strong><\/h3><p data-start=\"1699\" data-end=\"1926\"><strong><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-micron-technology-inc\/\">Micron Technology<\/a><\/strong> received the RED HOT CHILI\u2122 MUMAK last week. The decisive factors were the positive outlook for AI memory solutions, favorable industry fundamentals, and an initially positive technical picture.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3c02c9e elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"3c02c9e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"elementor-heading-title elementor-size-default\"><strong><a href=\"https:\/\/mumak.me\/en\/portfolio-updates\/red-hot-chili-mumak\/red-hot-chili-mumak-of-the-week-micron-technology-ai-memory-in-focus\/\">RED HOT CHILI\u2122 MUMAK of the Week: Micron Technology \u2013 AI memory in focus<\/a><\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8f0ba38 elementor-widget elementor-widget-text-editor\" data-id=\"8f0ba38\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"1443\" data-end=\"1629\">However, the positive development has already been accompanied by a significant price increase. Revolution Medicines therefore remains a company that should continue to be closely monitored.<\/p><p class=\"PDq2pG_selectionAnchorContainer\" data-start=\"1934\" data-end=\"2039\">Since then, the share price has weakened. The position is currently around 7.1% below its purchase price.<\/p><p data-start=\"2041\" data-end=\"2209\">The upcoming quarterly results from <strong><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-micron-technology-inc\/\">Micron<\/a><\/strong> remain the next important test. Until then, the position requires patience and does not warrant a renewed award.<\/p><h3 data-start=\"2211\" data-end=\"2250\">Mixed signals within the UMBRELLA Strategy<\/h3><ul data-start=\"2320\" data-end=\"2458\"><li data-section-id=\"i0s0fp\" data-start=\"2320\" data-end=\"2352\"><strong><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-johnson-johnson\/\">Johnson &amp; Johnson<\/a><\/strong>: approx. +8.6%<\/li><li data-section-id=\"124nwu9\" data-start=\"2353\" data-end=\"2377\"><strong><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-eli-lilly-and-company\/\">Eli Lilly<\/a><\/strong>: approx. +3.3%<\/li><li data-section-id=\"1kz5404\" data-start=\"2378\" data-end=\"2399\"><strong><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-bayer-ag\/\">Bayer<\/a><\/strong>: approx. +10.5%<\/li><li data-section-id=\"1ieig4m\" data-start=\"2400\" data-end=\"2421\"><strong><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-spacex\/\">SpaceX<\/a><\/strong>: approx. +2.5%<\/li><li data-section-id=\"40qrxf\" data-start=\"2422\" data-end=\"2458\"><strong><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-palantir-technologies-inc\/\">Palantir Technologies<\/a><\/strong>: approx. +0.3%<\/li><\/ul><p data-start=\"2460\" data-end=\"2633\">However, none of these companies currently combine a sufficiently strong new catalyst with favorable market sentiment and convincing technical momentum.<\/p><p data-start=\"2635\" data-end=\"2810\">At the same time, <strong><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-mercadolibre-inc\/\">MercadoLibre<\/a><\/strong>, <strong><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-rheinmetall\/\">Rheinmetall<\/a><\/strong>, <strong><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-micron-technology-inc\/\">Micron Technology<\/a><\/strong>, and <strong><a href=\"https:\/\/mumak.me\/en\/inside-umbrella\/stocks\/stock-tkms\/\">TKMS<\/a><\/strong> are trading below their respective purchase prices. Their long-term investment theses continue to be monitored.<\/p><h3 data-start=\"2812\" data-end=\"2821\"><strong data-start=\"2812\" data-end=\"2821\">Key Takeaway<\/strong><\/h3><p data-start=\"2823\" data-end=\"2879\">No <strong>RED HOT CHILI\u2122 MUMAK<\/strong> will be awarded this week.<\/p><p data-start=\"2881\" data-end=\"3158\">The combination of limited short-term catalysts, mixed market sentiment, and weaker technical signals currently prevents any company in the portfolio from achieving a sufficiently strong alignment across all five MUMAK\u00ae analysis categories.<\/p><h4 data-start=\"3160\" data-end=\"3171\"> <\/h4><h4 class=\"PDq2pG_selectionAnchorContainer\" data-start=\"3160\" data-end=\"3171\"><strong data-start=\"3160\" data-end=\"3171\">Note<\/strong><\/h4><p data-start=\"3173\" data-end=\"3363\">At any given time, there can only be one RED HOT CHILI\u2122 MUMAK. In weeks where no company meets the required criteria, the award may remain unassigned.<\/p><p data-start=\"3365\" data-end=\"3643\">The RED HOT CHILI\u2122 MUMAK is an internal award of the MUMAK\u00ae UMBRELLA Strategy. It identifies the company that, at the time of publication, shows the highest alignment across the five MUMAK\u00ae analysis categories within our analysis universe.<\/p><p data-start=\"3645\" data-end=\"3907\" data-is-last-node=\"\" data-is-only-node=\"\">Neither this award nor the decision not to award it constitutes investment advice or a recommendation to buy, hold, or sell. Investments are subject to risks and can lead to the complete loss of invested capital.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>The RED HOT CHILI\u2122 MUMAK will not be awarded this week. <\/p>\n","protected":false},"author":2,"featured_media":2171,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[220],"tags":[566,360,409,158],"aktie":[],"class_list":["post-9496","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-red-hot-chili-mumak","tag-micron-technology","tag-aktienanalyse","tag-revolution-medicines","tag-umbrella-strategy"],"acf":[],"_links":{"self":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/9496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/comments?post=9496"}],"version-history":[{"count":7,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/9496\/revisions"}],"predecessor-version":[{"id":9517,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/posts\/9496\/revisions\/9517"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/media\/2171"}],"wp:attachment":[{"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/media?parent=9496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/categories?post=9496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/tags?post=9496"},{"taxonomy":"aktie","embeddable":true,"href":"https:\/\/mumak.me\/en\/wp-json\/wp\/v2\/aktie?post=9496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}